A series of biomarker discoveries developed by researchers at Mayo Clinic and the University of Minnesota have resulted in a licensed technology that will benefit prostate cancer patients globally. The research that led to the discoveries and subsequent patents was funded by one of the first grants awarded by the Minnesota Partnership. Mayo Clinic's Eric Wieben, Ph.D., program manager for the Partnership, says, "This is a great example of why the Partnership was created. A relatively small amount of initial support led to larger government grants and a successful outcome in a diagnostic test that will no doubt save lives and improve treatment."
Click here for news release